FC Stock News
Monday, October 30, 2006
Point Therapeutics Reports Positive Results
Point Therapeutics Inc. (POTP) reported positive results for talabostat in an osteosarcoma model. Shares of the biopharmaceutical gained 24 cents to close at $1.49.
posted by FC Market News at
10:07 AM
0 Comments:
Post a Comment
<< Home
About Me
Name:
FC Market News
View my complete profile
Previous Posts
Nextest Warns Of Slowdown
Profit Falls For Georgia Gulf
Hittite's Forecast Disappoints
Mannatech Being Investigated
Volcom's Revenue Rises
Positive Results For Vertex
Higher Earnings For Harman International
Renovis Reports Failed Drug Test
Oracle Competes Against Red Hat
Universal American Receives Buyout Offer
0 Comments:
Post a Comment
<< Home